Label-Free Techniques for Drug Discovery: Surface Plasmon Resonance (SPR) and MALDI Mass Spectrometry for Primary (HTS) and Secondary Screening
The webinar will update on latest developments in MALDI mass spectrometry for high-throughput screening and CPD profiling (rapifleX MALDI PharmaPulse) and introduce Bruker's new surface plasmon resonance (SPR) instrument, the SIERRA SPR-32. Beside technical details explaining the latest developments, synergies between MALDI mass spectrometry and SPR will be discussed.
Dr. Meike Hamester
Director Small Molecule Pharma Business
Dr. Meike Hamester studied chemistry at the University of Hamburg, Germany. She worked 18 years in the field of mass spectrometry at Thermo Fisher Scientific. Since 2012 Meike works for BRUKER Daltonik in Bremen.
Dipl.-Ing. Sven Malik
Senior Application Specialist
Dipl. -Ing. Sven Malik studied Bioprocess-Engineering at TU Dresden. He worked 8 years in the field of surface plasmon resonance. Since 2012 Sven worked for Sierra Sensors GmbH (now Bruker).
- Primary and Secondary Screening in Drug Discovery
- Label-free technologies to reduce artefacts / importance of controls in SPR experiments
- Kinetic characterization: Determination of KDon- and KDoff-rates of compounds (SPR)
- Automation strategies to maximize throughput (SPR and MALDI)